SEC Form 4 · accession 0001193125-26-377207
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Subhashis Banerjee
Officer — Chief Medical Officer
Period of report
Aug 27, 2026
Accepted (ET)
Aug 31, 2026 · 7:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001817241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 27, 2026 | M | 5,306 | $1.92 | A | 150,269 | D | |
| Common StockF2 | Aug 27, 2026 | S | 8,222 | $12.0087 | D | 142,047 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $1.92 | Aug 27, 2026 | M | 5,306 | D | — | Apr 7, 2035 | Common Stock | 5,306 | 74,265 | D |
Explanation of responses
- F1The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.
- F2The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F325% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months.